Optimized Administration of the M4 PAM VU0467154 Demonstrates Broad Efficacy, but Limited Effective Concentrations in Mecp2+/

Optimized Administration of the M₄ PAM VU0467154 Demonstrates Broad Efficacy, but Limited Effective Concentrations in Mecp2^+/– Mice

Published:2022-06-07 Issue:13 Volume:13 Page:1891-1901
ISSN:1948-7193
Container-title:ACS Chemical Neuroscience
language:en
Short-container-title:ACS Chem. Neurosci.

Author:

Cikowski Jakub¹²,Holt Calista¹²,Arthur Bright³⁴⁵,Smith Mackenzie¹²,Gonzalez Sonia¹²,Lindsley Craig W.³⁴⁵⁶⁷^ORCID,Niswender Colleen M.³⁴⁵⁶⁸,Gogliotti Rocco G.¹²³⁴^ORCID

Affiliation:

1. Department of Molecular Pharmacology and Neuroscience, Loyola University Chicago, Maywood, Illinois 60153, United States

2. Edward Hines Jr. VA Hospital, Hines, Illinois 60141, United States

3. Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232, United States

4. Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States

5. Vanderbilt Kennedy Center, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States

6. Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee 37232, United States

7. Department of Chemistry, Vanderbilt University, Nashville, Tennessee 37232, United States

8. Vanderbilt Brain Institute, Vanderbilt University, Nashville, Tennessee 37232, United States

Funder

National Institute of Neurological Disorders and Stroke

International Rett Syndrome Foundation

Brain and Behavior Research Foundation

National Institute of Mental Health

Publisher

American Chemical Society (ACS)

Subject

Cell Biology,Cognitive Neuroscience,Physiology,Biochemistry,General Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acschemneuro.2c00113

Reference40 articles.

1. Rett syndrome: clinical and molecular update

2. Rett syndrome

3. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2

4. Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT co-repressor

5. MeCP2 mutations: progress towards understanding and treating Rett syndrome

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potentiation of the muscarinic acetylcholine receptor 1 modulates neurophysiological features in a mouse model of Rett syndrome;Neurotherapeutics;2024-07

2. Activation of M₄ muscarinic receptors in the striatum reduces tic‐like behaviours in two distinct murine models of Tourette syndrome;British Journal of Pharmacology;2024-04-30